Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above.

Trial Profile

Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A
  • Indications Influenza A virus H1N1 subtype
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
  • Most Recent Events

    • 08 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Dec 2009 Planned end date changed from 1 Nov 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
    • 27 Oct 2009 Interim results reported in GlaxoSmithKline media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top